October 25, 2021
Concentration of Evobrutinib, a Brutons Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study
Background: Evobrutinib, a highly selective Brutons tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg...
October 25, 2021
The Effect of Evobrutinib, a Brutons Tyrosine Kinase Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis
Background: Evobrutinib is a highly selective Brutons tyrosine kinase inhibitor targeting B cells and myeloid cells. A phase 2 randomized...